PE20161094A1 - Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos - Google Patents
Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericosInfo
- Publication number
- PE20161094A1 PE20161094A1 PE2016001214A PE2016001214A PE20161094A1 PE 20161094 A1 PE20161094 A1 PE 20161094A1 PE 2016001214 A PE2016001214 A PE 2016001214A PE 2016001214 A PE2016001214 A PE 2016001214A PE 20161094 A1 PE20161094 A1 PE 20161094A1
- Authority
- PE
- Peru
- Prior art keywords
- sequence
- dengue virus
- plasmid
- protein
- seq
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 4
- 239000013612 plasmid Substances 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 3
- 101710088839 Replication initiation protein Proteins 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108091008146 restriction endonucleases Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a un plasmido recombinante que contiene el gen de la proteina E de cada serotipo del virus del dengue fusionado a la secuencia que codifica para el peptido senal de t-PA caracterizado porque se construye insertando: a) la secuencia que codifica para el 80% de la proteina de la envuelta viral (E) del virus del dengue sin la parte C-terminal de la proteina E, tal secuencia se amplifica usando los oligonucleotidos SEQ ID NO:3 y SEQ ID NO:4; o b) la secuencia que codifica para el dominio III de la proteina E del virus del dengue; tal secuencia se amplifica usando los oligonucleotidos SEQ ID NO: 5 y SEQ ID NO: 4. La secuencia de (a) esta contenida entre los nucleotidos 937 y 2131, y la secuencia de (b) esta contenida entre los nucleotidos 1822 y 2131, del genoma completo de DENV2, cepa New Guinea C (NGC). Posteriormente se lleva a cabo la clonacion de la secuencia en el plasmido pcTPA entre los sitios enzimaticos de las enzimas de restriccion EcoRV y XbaI1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161094A1 true PE20161094A1 (es) | 2016-10-22 |
Family
ID=43825448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000411A PE20121171A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
| PE2016001214A PE20161094A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000411A PE20121171A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10357558B2 (es) |
| EP (1) | EP2484376A4 (es) |
| CN (1) | CN102711817B (es) |
| BR (1) | BRPI0904020B8 (es) |
| CL (1) | CL2012000783A1 (es) |
| CO (1) | CO6541529A2 (es) |
| CU (1) | CU24060B1 (es) |
| EC (1) | ECSP12012131A (es) |
| PE (2) | PE20121171A1 (es) |
| WO (1) | WO2011038473A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6818548B2 (ja) * | 2013-03-15 | 2021-01-20 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法 |
| AU2014281713A1 (en) | 2013-06-21 | 2015-11-12 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| ITRM20130458A1 (it) | 2013-08-05 | 2015-02-05 | Internat Ct For Genetic En Gineering And | Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope |
| BR112017013270A2 (pt) * | 2014-12-22 | 2018-03-06 | Merck Sharp & Dohme | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| BR112021003962A2 (pt) | 2018-09-05 | 2021-05-25 | Takeda Vaccines, Inc. | dose unitária de vacina contra dengue e sua administração |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
| US6881723B1 (en) * | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
| NZ535690A (en) * | 2002-02-26 | 2009-04-30 | Maxygen Inc | Novel flavivirus antigens |
| ZA200802176B (en) * | 2005-08-10 | 2009-08-26 | Acambis Inc | Vaccination against dengue virus infection |
| BRPI0614265A2 (pt) | 2005-08-10 | 2011-03-22 | Acambis Inc | uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas |
| CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| EP2462930B1 (en) * | 2006-11-09 | 2017-05-31 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| CA2708668C (en) * | 2008-01-11 | 2019-03-05 | Vgx Pharmaceuticals, Llc | Vaccines against multiple subtypes of dengue virus |
-
2009
- 2009-10-01 BR BRPI0904020A patent/BRPI0904020B8/pt active IP Right Grant
-
2010
- 2010-08-01 PE PE2012000411A patent/PE20121171A1/es active IP Right Grant
- 2010-08-01 CN CN201080052438.4A patent/CN102711817B/zh not_active Expired - Fee Related
- 2010-08-01 EP EP10819756.7A patent/EP2484376A4/en not_active Withdrawn
- 2010-08-01 US US13/499,697 patent/US10357558B2/en not_active Expired - Fee Related
- 2010-08-01 WO PCT/BR2010/000323 patent/WO2011038473A1/pt not_active Ceased
- 2010-08-01 PE PE2016001214A patent/PE20161094A1/es unknown
-
2012
- 2012-03-29 CL CL2012000783A patent/CL2012000783A1/es unknown
- 2012-04-02 CU CU20120057A patent/CU24060B1/es active IP Right Grant
- 2012-04-26 CO CO12069004A patent/CO6541529A2/es unknown
- 2012-05-04 EC ECSP12012131 patent/ECSP12012131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6541529A2 (es) | 2012-10-16 |
| EP2484376A4 (en) | 2014-01-22 |
| ECSP12012131A (es) | 2013-02-28 |
| BRPI0904020A2 (pt) | 2011-06-14 |
| WO2011038473A8 (pt) | 2012-07-19 |
| CU24060B1 (es) | 2014-12-26 |
| US10357558B2 (en) | 2019-07-23 |
| BRPI0904020B1 (pt) | 2019-11-12 |
| EP2484376A1 (en) | 2012-08-08 |
| CU20120057A7 (es) | 2013-01-30 |
| PE20121171A1 (es) | 2012-08-30 |
| WO2011038473A1 (pt) | 2011-04-07 |
| US20120251570A1 (en) | 2012-10-04 |
| CL2012000783A1 (es) | 2013-03-22 |
| BRPI0904020B8 (pt) | 2021-05-25 |
| CN102711817B (zh) | 2016-10-26 |
| CN102711817A (zh) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161094A1 (es) | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos | |
| Li et al. | A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques | |
| MX2024012403A (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
| WO2009124312A3 (en) | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same | |
| NZ593598A (en) | Optimized antiviral vaccines with improved cellular immunogenicity | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| CL2010000883A1 (es) | Acidos nucleicos que comprenden secuencias de un virus de gastroenteritis transmisible (tgev), secuencias que codifican epitopes neutralizadores de orf5 de prrsv y al menos otro peptido capaz de aumentar una respuesta inmune contra prrsv; vector , celula, particula viral, vacuna y composicion que lo comprenden; polipeptido codificado | |
| MX339241B (es) | Vacunas novedosas contra sub-tipos multiples de virus de influenza. | |
| NO20056074L (no) | Hoy titer rekombinante influensavira til vaksiner og genterapi | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| CY1105680T1 (el) | Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| JP2009544333A5 (es) | ||
| NZ580378A (en) | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| PE20090683A1 (es) | Peptidos de senalizacion | |
| KR100469936B1 (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
| EA202092990A2 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу | |
| MX2024004293A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| CL2009001249A1 (es) | Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia. | |
| TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
| CU23245A1 (es) | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS | |
| EP1816203A4 (en) | FOR CORONAVIRUS-SIMILAR PARTICLES CODING EXPRESSION VECTOR | |
| AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes |